Current anticoagulant therapies for the prevention and treatment of thromboembolic disorders have many drawbacks: vitamin K antagonists interact with food and drugs and require frequent laboratory monitoring, and heparins require parenteral administration...
Keywords: Factor Xa inhibitor, Venous thrombosis, prophylaxis, rivaroxaban, oral anticoagulant
03/2007 | Thrombosis and Haemostasis, Schattauer